Newswire (Published: Tuesday, October 5, 2021, Received: Tuesday, October 5, 2021, 5:58:01 PM CDT)

Word Count: 679

2021 OCT 05 (NewsRx) -- By a News Reporter-Staff News Editor at NewsRx Medical Devices Daily -- A new study on Drugs and Therapies - Radiotherapy is now available. According to news originating from Chicago, Illinois, by NewsRx correspondents, research stated, “Mesh brachytherapy is a special type of a permanent brachytherapy implant: it uses low-energy radioactive seeds in an absorbable mesh that is sutured onto the tumor bed immediately after a surgical resection. This treatment offers low additional risk to the patient as the implant procedure is carried out as part of the tumor resection surgery.”

Financial supporters for this research include Varian Medical Systems, Inc., CivaTech Oncology, Inc., Isoray Medical, Inc.

Our news journalists obtained a quote from the research from Northwestern University, “Mesh brachytherapy utilizes identification of the tumor bed through direct visual evaluation during surgery or medical imaging following surgery through radiographic imaging of radio-opaque markers within the sources located on the tumor bed. Thus, mesh brachytherapy is customizable for individual patients. Mesh brachytherapy is an intraoperative procedure involving mesh implantation and potentially real-time treatment planning while the patient is under general anesthesia. The procedure is multidisciplinary and requires the complex coordination of multiple medical specialties. The preimplant dosimetry calculation can be performed days beforehand or expediently in the operating room with the use of lookup tables. In this report, the guidelines of American Association of Physicists in Medicine (AAPM) are presented on the physics aspects of mesh brachytherapy. It describes the selection of radioactive sources, design and preparation of the mesh, preimplant treatment planning using a Task Group (TG) 43-based lookup table, and postimplant dosimetric evaluation using the TG-43 formalism or advanced algorithms. It introduces quality metrics for the mesh implant and presents an example of a risk analysis based on the AAPM TG-100 report. Recommendations include that the preimplant treatment plan be based upon the TG-43 dose calculation formalism with the point source approximation, and the postimplant dosimetric evaluation be performed by using either the TG-43 approach, or preferably the newer model-based algorithms (viz., TG-186 report) if available to account for effects of material heterogeneities. To comply with the written directive and regulations governing the medical use of radionuclides, this report recommends that the prescription and written directive be based upon the implanted source strength, not target-volume dose coverage. The dose delivered by mesh implants can vary and depends upon multiple factors, such as postsurgery recovery and distortions in the implant shape over time. For the sake of consistency necessary for outcome analysis, prescriptions based on the lookup table (with selection of the intended dose, depth, and treatment area) are recommended, but the use of more advanced techniques that can account for real situations, such as material heterogeneities, implant geometric perturbations, and changes in source orientations, is encouraged in the dosimetric evaluation.”

According to the news editors, the research concluded: “The clinical workflow, logistics, and precautions are also presented.”

This research has been peer-reviewed.

For more information on this research see: Recommendations for Intraoperative Mesh Brachytherapy: Report of Aapm Task Group No. 222. Medical Physics, 2021. Medical Physics can be contacted at: Wiley, 111 River St, Hoboken 07030-5774, NJ, USA. (American Association of Physicists in Medicine - www.aapm.org; Medical Physics - http://online.medphys.org/)

The news correspondents report that additional information may be obtained from Hualin Zhang, Northwestern University, Northwestern Memorial Hospital, Northwestern University Feinberg School of Medicine, Dept. of Radiation Oncology, Chicago, IL 60611, United States. Additional authors for this research include Wenzheng Feng, Mark J. Rivard, Elizabeth M. Carey, Robert A. Hearn, Sujatha Pai, Ravinder Nath, Yongbok Kim, Cynthia L. Thomason and Dale E. Boyce.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1002/mp.15191. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)

Companies

Varian Medical Systems Inc.
Northwestern Memorial Hospital

Places

North America
United States
Americas
Illinois
Chicago

Subjects

Science and Technology
      Scientific Research
            Medical Research
      Sciences
            Physical Sciences
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Health Sciences
            Medical Research
      Treatments and Therapies
            Radiation Therapy